As of 2026-04-02, the Relative Valuation of Halozyme Therapeutics Inc (HALO) is 80.36 USD. This relative valuation is based on P/E multiples. With the latest stock price at 65.40 USD, the upside of Halozyme Therapeutics Inc based on Relative Valuation is 22.9%.
The range of the Relative Valuation is 65.68 - 106.89 USD.
| Range | Selected | |
| Trailing P/E multiples | 24.5x - 27.9x | 24.7x |
| Forward P/E multiples | 23.3x - 31.5x | 27.8x |
| Fair Price | 65.68 - 106.89 | 80.36 |
| Upside | 0.4% - 63.4% | 22.9% |
| Date | P/E |
| 2026-04-01 | 24.36 |
| 2026-03-31 | 24.07 |
| 2026-03-30 | 23.14 |
| 2026-03-27 | 22.95 |
| 2026-03-26 | 23.57 |
| 2026-03-25 | 23.55 |
| 2026-03-24 | 23.11 |
| 2026-03-23 | 23.41 |
| 2026-03-20 | 23.62 |
| 2026-03-19 | 23.56 |
| 2026-03-18 | 23.71 |
| 2026-03-17 | 24.26 |
| 2026-03-16 | 23.94 |
| 2026-03-13 | 23.71 |
| 2026-03-12 | 23.67 |
| 2026-03-11 | 24.76 |
| 2026-03-10 | 25.25 |
| 2026-03-09 | 25.38 |
| 2026-03-06 | 25.09 |
| 2026-03-05 | 25.09 |
| 2026-03-04 | 26.08 |
| 2026-03-03 | 25.85 |
| 2026-03-02 | 26.01 |
| 2026-02-27 | 25.90 |
| 2026-02-26 | 25.78 |
| 2026-02-25 | 26.20 |
| 2026-02-24 | 26.20 |
| 2026-02-23 | 26.31 |
| 2026-02-20 | 26.44 |
| 2026-02-19 | 26.83 |
| 2026-02-18 | 27.27 |
| 2026-02-17 | 29.97 |
| 2026-02-13 | 29.59 |
| 2026-02-12 | 28.65 |
| 2026-02-11 | 29.61 |
| 2026-02-10 | 29.88 |
| 2026-02-09 | 29.97 |
| 2026-02-06 | 30.25 |
| 2026-02-05 | 29.21 |
| 2026-02-04 | 29.02 |
| 2026-02-03 | 28.48 |
| 2026-02-02 | 27.73 |
| 2026-01-30 | 26.71 |
| 2026-01-29 | 27.31 |
| 2026-01-28 | 27.12 |
| 2026-01-27 | 26.15 |
| 2026-01-26 | 26.02 |
| 2026-01-23 | 25.78 |
| 2026-01-22 | 26.55 |
| 2026-01-21 | 26.71 |